Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Tuesday 17 March, 2020

Morgan Stanley&CoLLC

Rule 38.5 - Replacement of ALLERGAN PLC

RNS Number : 4878G
Morgan Stanley & Co. LLC
17 March 2020
 

AMENDMENT Section (2a)

  FORM 38.5

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER  RULES, 2007 (AS AMENDED)

 

DEALINGS BY CONNECTED EXEMPT MARKET-MAKERS

 

1.  KEY INFORMATION

 Name of exempt market-maker

  Morgan Stanley & Co. LLC

 Company dealt in

  ALLERGAN PLC

 Class of relevant security to which the dealings being disclosed relate (Note 1)

  US$0.0001 ORDINARY SHARES

 Date of dealing

  12 MARCH 2020

 

 

2.  DEALINGS  (Note 2)

 

(a)  Purchases and sales

 Total number of relevant secuities accquired

 Highest price paid (Note 3)

 Lowest price paid (Note 3)

   1,278,607

 181.7100 USD

 172.8800 USD

 

 Total number of relevant secuities disposed

 Highest price paid (Note 3)

 Lowest price paid (Note 3)

   1,232,368

 181.7100 USD

 172.8800 USD

 

 

(b)  Derivatives transactions (other than options transactions)

 

 Product name, e.g. CFD

 Nature of transaction

  (Note 4)

 Number of relevant securities

  (Note 5)

 Price per unit

 N/A

 N/A

 N/A

 N/A

 

 

(c)  Options transactions in respect of existing relevant securities

 

i)  Writing, selling, purchasing or varying

 

 Product name, eg call option

 Writing, selling, purchasing, varying etc

 Number of securities to which the option relates (Note 5)

 Exercise Price

 Type, e.g American, European etc

 Expiry Date

 Option money paid/received per unit (Note 3)

 PUT

 SALE

 100

 165.0000

A

 17/04/2020

 5.7000 USD

 PUT

 SALE

 100

 155.0000

A

 15/05/2020

 6.0000 USD

 PUT

 SALE

 100

 165.0000

A

 17/04/2020

 6.1000 USD

 PUT

 SALE

 100

 150.0000

A

 19/06/2020

 6.1500 USD

 PUT

 SALE

 100

 160.0000

A

 19/06/2020

 6.5000 USD

 PUT

 SALE

 100

 160.0000

A

 15/05/2020

 6.6000 USD

 PUT

 SALE

 100

 155.0000

A

 19/06/2020

 6.8500 USD

 PUT

 SALE

 100

 165.0000

A

 15/05/2020

 7.6000 USD

 PUT

 SALE

 100

 160.0000

A

 19/06/2020

 7.7500 USD

 PUT

 SALE

 100

 160.0000

A

 19/06/2020

 7.8000 USD

 PUT

 SALE

 100

 160.0000

A

 19/06/2020

 7.8000 USD

 PUT

 SALE

 100

 160.0000

A

 19/06/2020

 7.8000 USD

 PUT

 SALE

 100

 160.0000

A

 19/06/2020

 7.8000 USD

 PUT

 SALE

 100

 160.0000

A

 19/06/2020

 7.8000 USD

 PUT

 SALE

 100

 160.0000

A

 19/06/2020

 7.8000 USD

 PUT

 SALE

 100

 180.0000

A

 20/03/2020

 8.1000 USD

 PUT

 SALE

 100

 180.0000

A

 01/05/2020

 9.8500 USD

 PUT

 SALE

 100

 185.0000

A

 01/05/2020

 12.2500 USD

 PUT

 SALE

 100

 180.0000

A

 19/06/2020

 13.2000 USD

 PUT

 SALE

 100

 185.0000

A

 17/04/2020

 13.8500 USD

 PUT

 SALE

 100

 185.0000

A

 17/04/2020

 13.8500 USD

 PUT

 SALE

 100

 180.0000

A

 19/06/2020

 14.4000 USD

 PUT

 SALE

 100

 180.0000

A

 19/06/2020

 14.4000 USD

 PUT

 SALE

 100

 180.0000

A

 19/06/2020

 14.4000 USD

 PUT

 SALE

 200

 180.0000

A

 15/01/2021

 16.4300 USD

 CALL

 SALE

 100

 160.0000

A

 19/06/2020

 24.5500 USD

 CALL

 SALE

 100

 155.0000

A

 20/03/2020

 26.2500 USD

 CALL

 SALE

 1,000

 155.0000

A

 20/03/2020

 26.2500 USD

 

(ii) Exercising

 

 Product name, eg call option

 Number of securities

 Exercise price per unit (Note 3)

 N/A

 N/A

 N/A 

 

 

3. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full Details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 Date of disclosure

 17 MARCH 2020

 Contact Name

Craig Horsley

 Telephone Number

+44(141) 245 7736

 Name of offeree/offeror with which connected

ABBVIE INC.

Nature of connection (Note 6)

Advisory

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEEALDXFFPEEFA

a d v e r t i s e m e n t